Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Angle reviewing board structure as two directors exit

(Sharecast News) - Shares in Angle dropped sharply on Friday after the cancer treatment tech firm announcement the abrupt resignation of two boardmembers. Angle which last week disappointed investors with a cautious outlook alongside its annual results, said that non-executive director Brian Howlett is set to leave the board after 12 years of service at the upcoming AGM, scheduled for 30 June.

Meanwhile, non-executive director Juliet Thompson has resigned with immediate effect, the company also confirmed.

Angle, whose technology harvests circulating tumour cell (CTC) from the blood for analysis, specified no reasons for each boardmembers' decisions.

"The Company is reviewing the structure and composition for the Board moving forward," Angle said.

On 28 May, Angle delivered strong results for 2024, but pointed to only "modest" growth in 2025 following a 31% surge in revenues last year.

Angle said that recent market turbulence, the uncertain macro environment and further reductions to research funding across academic and government labs has "adversely impacted the company's year-to-date revenues".

Shares were down 7.4% at 7.40p by 0817 BST. The stock has now fallen 24% since Angle's annual results announcement.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.